Overexpression of adenylate cyclase-associated protein 1 may predict brain metastasis in non-small cell lung cancer

Xie,Shuan-Shuan; Tan,Min; Lin,Hai-Yan; Xu,Lei; Shen,Chang-Xing; Yuan,Qing; Song,Xiao-Lian; Wang,Chang-Hui

doi:10.3892/or.2014.3577

Overexpression of adenylate cyclase-associated protein 1 may predict brain metastasis in non-small cell lung cancer

Authors:
- Shuan-Shuan Xie
- Min Tan
- Hai-Yan Lin
- Lei Xu
- Chang-Xing Shen
- Qing Yuan
- Xiao-Lian Song
- Chang-Hui Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, P.R. China
Published online on: October 30, 2014 https://doi.org/10.3892/or.2014.3577
Pages: 363-371

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to establish a biomarker risk model for predicting brain metastasis (BM) in non-small cell lung cancer (NSCLC). The model comprises 120 cases of NSCLC that were treated and followed up for 4 years. The patients were divided into the BM (n=50) and non-BM (other visceral metastasis and those without recurrence) (n=70) groups. Immunohistochemical and western blot analyses were performed in metastatic tissues of NSCLC. Multivariate regression analysis was performed to correlate the immunoreactive cyclase-associated protein 1 (CAP1) signal with BM. Survival analyses were performed by using the Kaplan-Meier method. CAP1 protein content and immunoreactivity were significantly increased in BM specimens compared to other-metastatic specimens. The survival analysis revealed that CAP1 overexpression was significantly associated with survival (P<0.05). The ROC test suggested that the area under the curve was 73.33% (P<0.001; 95% CI, 63.5-83.2%). When P=0.466, the sensitivity and specificity reached 79.5 and 67.1%, respectively. These findings suggested that CAP1 is involved in the BM of NSCLC, and that elevated levels of CAP1 expression may indicate a poor prognosis for patients with BM. The CAP1 molecular model may be useful in the prediction of the risk of BM in NSCLC.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Walling J: Chemotherapy for advanced non-small-cell lung cancer. Respir Med. 88:649–657. 1994. View Article : Google Scholar : PubMed/NCBI
3	Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
4	Strauss GM, Herndon JE, Sherman DD, et al: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol. 10:1237–1244. 1992.PubMed/NCBI
5	Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 13:1880–1892. 1995.PubMed/NCBI
6	Andre F, Grunenwald D, Pujol JL, et al: Patterns of relapse of N2 non-small-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer. 91:2394–2400. 2001. View Article : Google Scholar : PubMed/NCBI
7	Carmichael J, Crane JM, Bunn PA, et al: Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys. 14:455–459. 1998. View Article : Google Scholar
8	Cox JD, Stanley K, Petrovich Z, et al: Cranial irradiation in cancer of the lung of all cell types. JAMA. 245:469–472. 1981. View Article : Google Scholar : PubMed/NCBI
9	Arriagada R, Le Chevalier T, Borie F, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 87:183–190. 1995. View Article : Google Scholar : PubMed/NCBI
10	Shaw EG, Su JQ, Eagan RT, et al: Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol. 12:2327–2332. 1994.PubMed/NCBI
11	Langer CJ and Mehta MP: Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 23:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
12	Tan M, Song X, Zhang G, et al: Overexpression of adenylate cyclase-associated protein 1 is associated with metastasis of lung cancer. Oncol Rep. 30:1639–1644. 2013.PubMed/NCBI
13	Delattre JY, Krol G, Thaler HT and Posner JB: Distribution of brain metastases. Arch Neurol. 45:741–744. 1988. View Article : Google Scholar : PubMed/NCBI
14	Fedor-Chaiken M, Deschenes RJ and Broach JR: SRV2, a gene required for RAS activation of adenylate cyclase in yeast. Cell. 61:329–340. 1990. View Article : Google Scholar : PubMed/NCBI
15	Field J, Vojtek A, Ballester R, et al: Cloning and characterization of CAP, the S. cerevisiae gene encoding the 70 kd adenylyl cyclase-associated protein. Cell. 61:319–327. 1990. View Article : Google Scholar : PubMed/NCBI
16	Matviw H, Yu G and Young D: Identification of a human cDNA encoding a protein that is structurally and functionally related to the yeast adenylyl cyclase-associated CAP proteins. Mol Cell Biol. 12:5033–5040. 1992.PubMed/NCBI
17	Freeman NL, Chen Z, Horenstein J, Weber A and Field J: An actin monomer binding activity localizes to the carboxyl-terminal half of the Saccharomyces cerevisiae cyclase-associated protein. J Biol Chem. 270:5680–5685. 1995. View Article : Google Scholar : PubMed/NCBI
18	Moriyama K and Yahara I: Human CAP1 is a key factor in the recycling of cofilin and actin for rapid actin turnover. J Cell Sci. 115:1591–1601. 2002.PubMed/NCBI
19	Hubberstey AV and Mottillo EP: Cyclase-associated proteins: CAPacity for linking signal transduction and actin polymerization. FASEB J. 16:487–499. 2002. View Article : Google Scholar : PubMed/NCBI
20	Loisel TP, Boujemaa R, Pantaloni D and Carlier MF: Reconstitution of actin-based motility of Listeria and Shigella using pure proteins. Nature. 401:613–616. 1999. View Article : Google Scholar : PubMed/NCBI
21	Yamazaki K, Takamura M, Masugi Y, et al: Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility. Lab Invest. 89:425–432. 2009. View Article : Google Scholar : PubMed/NCBI